Citigroup
GRTX

Citigroup’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Citigroup’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,599
Closed -$15K – 6459
2022
Q2 		$15K Buy
+11,599
New +$19.9K ﹤0.01% 5172
2021
Q2 		– Sell
-609
Closed -$5K – 6474
2021
Q1 		$5K Sell
609
-1,005
-62% -$11K ﹤0.01% 5915
2020
Q4 		$17K Buy
1,614
+1,183
+274% +$12.9K ﹤0.01% 6754
2020
Q3 		$4K Sell
431
-692
-62% -$5.48K ﹤0.01% 7163
2020
Q2 		$8K Buy
1,123
+423
+60% +$4.49K ﹤0.01% 7153
2020
Q1 		$7K Sell
700
-267
-28% -$3.44K ﹤0.01% 7192
2019
Q4 		$13K Buy
+967
New +$11.8K ﹤0.01% 7121

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup's GRTX Position: Q3 2022 in Review

Citigroup sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q3 2022, closing a stake of 11,599 shares — an estimated $15K sold.

Citigroup first reported a position in GRTX in Q4 2019 and held it in 7 quarters. The position peaked at $17K in Q4 2020. 33 funds tracked by Wall St. Rank hold GRTX as of Q3 2022.

  • Citigroup reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 11,599 Galera Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $15K.
  • Citigroup first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
  • Citigroup's Galera Therapeutics, Inc. Common Stock position peaked at $17K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.